nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
An emerging interstitial lung disease
|
George, Peter M |
|
2016 |
4 |
9 |
p. 762- 1 p. |
artikel |
2 |
Anti-acid treatment in patients with IPF: interpret results from post-hoc, subgroup, and exploratory analyses with great caution
|
Raghu, Ganesh |
|
2016 |
4 |
9 |
p. e46-e47 nvt p. |
artikel |
3 |
Anti-acid treatment in patients with IPF: interpret results from post-hoc, subgroup, and exploratory analyses with great caution – Authors' reply
|
Kreuter, Michael |
|
2016 |
4 |
9 |
p. e48- 1 p. |
artikel |
4 |
Awareness campaigns improve diagnosis, but at what cost?
|
Cagney, Hannah |
|
2016 |
4 |
9 |
p. 697-698 2 p. |
artikel |
5 |
Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis
|
Pavord, Ian D |
|
2016 |
4 |
9 |
p. 731-741 11 p. |
artikel |
6 |
Calls to suspend European sales of erlotinib for lung cancer
|
Tanday, Sanjay |
|
2016 |
4 |
9 |
p. 691- 1 p. |
artikel |
7 |
Cardiovascular disease in COPD: time to quash a silent killer
|
Bolton, Charlotte E |
|
2016 |
4 |
9 |
p. 687-689 3 p. |
artikel |
8 |
Case finding for COPD in general practice
|
van Weel, Chris |
|
2016 |
4 |
9 |
p. 679-681 3 p. |
artikel |
9 |
Don't forget the diet
|
The Lancet Respiratory Medicine, |
|
2016 |
4 |
9 |
p. 675- 1 p. |
artikel |
10 |
Eosinophils in COPD: the Janus of phenotyping response to therapy?
|
Bhatt, Surya P |
|
2016 |
4 |
9 |
p. 681-683 3 p. |
artikel |
11 |
Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial
|
Gonem, Sherif |
|
2016 |
4 |
9 |
p. 699-707 9 p. |
artikel |
12 |
Graphite design
|
Wilton, Jayne |
|
2016 |
4 |
9 |
p. 698- 1 p. |
artikel |
13 |
Implementation planning for lung cancer screening: five major challenges
|
Field, John K |
|
2016 |
4 |
9 |
p. 685-687 3 p. |
artikel |
14 |
Important—if uneven—strides towards respiratory health in the UK
|
Furlow, Bryant |
|
2016 |
4 |
9 |
p. 692-693 2 p. |
artikel |
15 |
Increasing scrutiny for the health hazards of indoor air
|
Furlow, Bryant |
|
2016 |
4 |
9 |
p. 690- 1 p. |
artikel |
16 |
Lung cancer screening: latest developments and unanswered questions
|
van der Aalst, Carlijn M |
|
2016 |
4 |
9 |
p. 749-761 13 p. |
artikel |
17 |
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial
|
Tashkin, Donald P |
|
2016 |
4 |
9 |
p. 708-719 12 p. |
artikel |
18 |
New generation of satellites will shed light on respiratory disease
|
Furlow, Bryant |
|
2016 |
4 |
9 |
p. 695-696 2 p. |
artikel |
19 |
Prostaglandin D2 receptor antagonism: a novel therapeutic option for eosinophilic asthma?
|
Brusselle, Guy G |
|
2016 |
4 |
9 |
p. 676-677 2 p. |
artikel |
20 |
Scleroderma Lung Study II—clarity or obfuscation?
|
Denton, Christopher P |
|
2016 |
4 |
9 |
p. 678-679 2 p. |
artikel |
21 |
Screening for sleep-disordered breathing: the continuing search for a reliable predictive questionnaire
|
McNicholas, Walter T |
|
2016 |
4 |
9 |
p. 683-685 3 p. |
artikel |
22 |
Shorter courses of antibiotic treatment for patients with pneumonia
|
Tanday, Sanjay |
|
2016 |
4 |
9 |
p. 691- 1 p. |
artikel |
23 |
Targeted case finding for chronic obstructive pulmonary disease versus routine practice in primary care (TargetCOPD): a cluster-randomised controlled trial
|
Jordan, Rachel E |
|
2016 |
4 |
9 |
p. 720-730 11 p. |
artikel |
24 |
The NoSAS score for screening of sleep-disordered breathing: a derivation and validation study
|
Marti-Soler, Helena |
|
2016 |
4 |
9 |
p. 742-748 7 p. |
artikel |
25 |
Thermal vapour ablation to reduce segmental volume in patients with severe emphysema: STEP-UP 12 month results
|
Shah, Pallav L |
|
2016 |
4 |
9 |
p. e44-e45 nvt p. |
artikel |
26 |
Using a bronchial airway gene expression classifier
|
Vermaelen, Karim |
|
2016 |
4 |
9 |
p. 694- 1 p. |
artikel |